The profile of refractory chronic cluster headache
Neurological Sciences · 2025
DOI: 10.1007/s10072-024-07708-0 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neurological Sciences, 2025. Verfasst von Javier A Membrilla und 14 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Hospital Universitari Francesc de Borja, Avinguda de la Medicina, 6, Gandia, 46702, València, Spain. membrilla_jav@gva.es. Hauptthemen laut MEDLINE: Cluster Headache. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Chronic cluster headache (CCH) is a relatively rare primary headache disorder whose management is often challenging. The prevalence of refractory CCH (rCCH) is unknown. Our aim is to describe the frequency of rCCH within a population of CCH, define the clinical profile of the refractory patients and the treatments they underwent. METHODS: We conducted a cross-sectional study through a review of the medical records of CCH patients in six hospitals in Madrid, Spain. Data on epidemiological, clinical presentation, treatment and disease activity at the moment were collected. The European Headache Federation diagnostic criteria were used for rCCH definition. High disease activity was defined as having at least 3 severe attacks per week that impact quality of life despite treatment. Non-rCCH and rCCH groups were compared. RESULTS: 88 CCH patients were analyzed, 68.2% (60/88) met rCCH criteria at some point in their evolution. A longer diagnostic delay (4.6 ± 7.1 vs. 3.2 ± 3.7 years, p = 0.017) was observed in rCCH. All rCCH patients tried therapies without established evidence from randomized clinical trials. OnabotulinumtoxinA and galcanezumab were initiated in 77.3% (68/88) and 5.7% (5/88), but discontinued in 52.9% (36/68) and 60.0% (3/5), respectively. Occipital nerve stimulation (ONS) was implanted in 29.6% (26/88), with 50.0% (13/26) still active. Other treatment options are described and discussed. Despite treatment, 60.2% (53/88) still have high disease activity. CONCLUSION: CCH is a disorder with poor prognosis, meeting refractoriness criteria in more than half. OnabotulinumtoxinA and ONS could be the effective in refractory patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Hospital Universitari Francesc de Borja, Avinguda de la Medicina, 6, Gandia, 46702, València, Spain. membrilla_jav@gva.es.
- Neurology Department, Hospital Clínico San Carlos, Madrid, Spain.
- Medicine Department, Universidad Complutense, Madrid, Spain.
- Neurology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
- Neurology Department, Hospital Universitario La Princesa, Madrid, Spain.
- Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Zitieren
APA
Membrilla, J. A., Cuadrado, M. L., González-García, N., Porta-Etessam, J., Sánchez-Soblechero, A., Lozano Ros, A., Gonzalez-Martinez, A., Gago-Veiga, A. B., Quintas, S., Rodríguez Vico, J. S., Jaimes, A., Llorente Ayuso, L., Roa, J., Estebas, C., & Díaz-de-Terán, J. (2025). The profile of refractory chronic cluster headache. Neurological Sciences. https://doi.org/10.1007/s10072-024-07708-0
Vancouver
Membrilla JA, Cuadrado ML, González-García N, Porta-Etessam J, Sánchez-Soblechero A, Lozano Ros A, et al. The profile of refractory chronic cluster headache. Neurological Sciences. 2025. doi:10.1007/s10072-024-07708-0
BibTeX
@article{Membrilla2025,
author = {Membrilla, Javier A and Cuadrado, María-Luz and González-García, Nuria and Porta-Etessam, Jesús and Sánchez-Soblechero, Antonio and Lozano Ros, Alberto and Gonzalez-Martinez, Alicia and Gago-Veiga, Ana Beatriz and Quintas, Sonia and Rodríguez Vico, Jaime S and Jaimes, Alex and Llorente Ayuso, Lucía and Roa, Javier and Estebas, Carlos and Díaz-de-Terán, Javier},
title = {The profile of refractory chronic cluster headache},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-024-07708-0}
}
EUVIMED